Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco - 1 Apr 2004

Cinciripini Paul, Wetter David, Tomlinson Gail, Tsoh Janice, De Moor Carl, Cinciripini Lynn, Minna John

Abstract excerpt

This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism. Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy). Venlafaxine is an antidepressant that inhibits the reuptake of serotonin and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Affect
Share to Antidepressive Agents, Second-Generation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Counseling

Share to Cyclohexanols

Share to Nicotine

Share to Placebos

Share to Smoking Cessation

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 15203796
DOI: 10.1080/14622200410001676396

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.PMID 15203796Read ↗

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.Semantic proximity Read ↗

Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.Semantic proximity Read ↗

Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Pharmacogenetics of nicotine addiction: role of dopamine.Semantic proximity Read ↗

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Semantic proximity Read ↗

Helping smokers quit through pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetic investigation of smoking cessation treatment.Semantic proximity Read ↗

Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.